Making Contact: Two Free Agents Who Can Fix the Angels' Strikeout Crisis Following a brutal, high-strikeout season, the Los Angeles Angels must prioritize high-contact hitters this winter. Here's why ...
Secondary analysis of the Phase 3 MAESTRO-NASH trial demonstrated Rezdiffra improved histology and MRI-PDFF across common genetic variants ...
Madrigal Pharmaceuticals recently reported in the Journal of Hepatology that a pre-specified secondary analysis of the Phase ...
Madrigal Pharmaceuticals event puts genetics in focus Madrigal Pharmaceuticals (MDGL) drew fresh attention after publishing a ...
Older GLP-1s are also set to muscle in on this latent MASH market. (eranicle/iStock/Getty Images Plus) With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) ...
Rays optioned INF Nick Madrigal to Triple-A Durham.
Madrigal has a first-mover advantage in treating MASH, a type of fatty liver disease.
Madrigal Pharmaceuticals is developing resmetirom, a drug for non-alcoholic steatohepatitis and fatty liver disease, with promising trial results. Madrigal has a strong cash position and manageable ...
The Tampa Bay Rays have activated a veteran infielder, sending Nick Madrigal to Triple-A Durham.
PORT ST. LUCIE, Fla. — Nick Madrigal doesn’t sing. He isn’t planning on performing a postgame summer concert. He’s not expecting to bust out a spirit-lifting catchphrase. “No, no,” he said with a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results